Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental obesity pill, with increased weight loss at higher doses, IBD’s Ed Carson reports. Patients taking 100-miligram doses of Viking’s VK2735 lost 8.2% of their body weight after 28 days, or 6.8% more than those taking a placebo, and no patients taking the highest dose stopped taking it, according to the report. Other companies that make weight-loss drugs include Eli Lilly (LLY) and Novi Nordisk (NVO). Shares of Viking Therapeutics were up nearly 25% in premarket trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Boeing union rejects latest offer, Tesla reports Q3 beat: Morning Buzz
- Viking Therapeutics reports Q3 EPS (22c) , consensus (25c)
- Viking Therapeutics options imply 8.5% move in share price post-earnings
- Is VKTX a Buy, Before Earnings?
- Viking Therapeutics reports data from Phase 1b clinical trial of VK0214